

# COSMO PHARMACEUTICALS NV

ISIN: NL0011832936 WKN: 32590356 Asset Class: Stock

## Company



2024/08/16 17:31:02

Price

78.60 CHF

Difference ▲ 0.77% (0.60)



## Contact Details

COSMO PHARMACEUTICALS NV

Tel: +353-1-8170370

--

Fax: +353-1-8230718

Riverside II, Sir John

Web:

Rogerson's Quay

<http://www.cosmopharma.com>

2 Dublin

E-mail: -

## Company Profile

Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	95,042,000		302,246,000		285,823,000	
Common stock capital		4,241,000		4,504,000		4,726,000
Fixed assets	420,008,000		447,789,000		548,867,000	
Equity capital of a company		398,887,000		451,030,000		523,951,000
Cash and cash equivalents	46,742,000		183,487,000		205,739,000	
Accrued liabilities		519,000		400,000		496,000
Other assets	-		-		-	
Current liabilities		23,907,000		192,493,000		22,003,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		92,256,000		106,511,000		288,735,000
Different income		-		-		-
Other liabilities		2,970,000		1,564,000		2,478,000
Total assets	515,051,000	515,051,000	750,036,000	750,036,000	834,690,000	834,690,000

## Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	325	295	290
Equity ratio	78.69%	61.04%	63.69%
Debt-equity ratio	27.09%	63.83%	57.01%

## Others

	2023	2022	2021
Tax Expense Rate	408.88%	28.47%	34.22%

# COSMO PHARMACEUTICALS NV

ISIN: NL0011832936 WKN: 32590356 Asset Class: Stock

## Income statement

	2023	2022	2021
Turnover	90,140,000	102,471,000	70,321,000
Net income	-4,791,000	17,289,000	23,419,000
EBIT	6,274,829	32,694,260	15,293,556
Operating income before taxes	1,488,000	24,564,000	7,358,000
Cash Flow	29,223,000	31,100,000	12,209,000
Net interest income	-4,445,000	-6,354,000	-7,105,000
Research and development expenses	14,327,000	11,589,000	8,208,000
Income taxes	6,085,000	6,994,000	2,517,000
Result from investments in subsidiaries, associates and other	0	0	18,580,000
Revenues per employee	293,274	367,300	256,408

## Board of Directors

Alessandro Chà	Chairman of Supervisory Board
John O'SDea	Member of Supervisory Board
Maria Grazia Roncarolo	Member of Supervisory Board
Mauro Ajani	Member of Supervisory Board
Niall Donnelly	Member of Supervisory Board
Silvana Perretta	Member of Supervisory Board

## Members of Management Board

Alessandro Della Cha	Chairman of Managing Board
Biagio Viganò	Member of Executive Committee
Luigi Longo	Member of Executive Committee
Marco Lecchi	Member of Executive Committee
Niall Donnelly	Member of Executive Committee
Roberto Villa	Member of Executive Committee